公开(公告)号：US10111856B2

公开(公告)日：2018-10-30

申请号：US14888623

申请日：2014-05-07

Applicant: AMOREPACIFIC CORPORATION

Inventor： Hyun Jung Shin ,  Hyun Woo Jeong ,  Ji Hae Lee ,  Dae Jin Min ,  Dae Bang Seo ,  Sang Jun Lee

IPC: A61K31/37 ,  A61K36/48

Abstract: The present invention relates to a composition for, inter alia, preventing or treating a climacteric disease, or preventing or improving a climacteric skin symptom comprising a soybean extract comprising coumestrol as an active ingredient, and more specifically relates to a composition for, inter alia, preventing or treating a climacteric disease, or preventing or improving a climacteric skin symptom comprising a germinated and fermented soybean extract comprising coumestrol as an active ingredient.

公开(公告)号：US11576923B2

公开(公告)日：2023-02-14

申请号：US17031147

申请日：2020-09-24

Applicant: AMOREPACIFIC CORPORATION

Inventor： Yong Deog Hong ,  Hyun Woo Jeong

IPC: A61K36/00 ,  A61K31/704 ,  A61K36/258 ,  A61Q19/08 ,  A61K8/63 ,  A61P17/00 ,  A61K8/97

Abstract: The present disclosure relates to a composition comprising (20S,24R)-6-O-β-D-glucopyranosyl(1→2)-β-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, which is a novel ginsenoside, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof as an active ingredient. In addition, it relates to a method for improving skin elasticity or skin wrinkles, which comprises administering an effective amount of (20S,24R)-6-O-β-D-glucopyranosyl(1→2)-β-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof to a subject in need thereof. The novel ginsenoside, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof has a superior effect of improving skin elasticity and skin wrinkles.

公开(公告)号：US11000538B2

公开(公告)日：2021-05-11

申请号：US16666586

申请日：2019-10-29

Applicant: AMOREPACIFIC CORPORATION

Inventor： Yong Deog Hong ,  Hyun Woo Jeong

IPC: A61K31/7048 ,  C07J17/00 ,  A61K9/00 ,  A61P21/06

Abstract: The present specification relates to a composition containing novel (20S,24R)-6-O-β-D-glucopyranosyl(1→2)-β-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof as an active ingredient. The composition exhibits an excellent exercise ability enhancing effect and anti-fatigue effect.

公开(公告)号：US11000537B2

公开(公告)日：2021-05-11

申请号：US16656029

申请日：2019-10-17

Applicant: AMOREPACIFIC CORPORATION

Inventor： Yong Deog Hong ,  Hyun Woo Jeong

IPC: A61K31/7048 ,  A61P3/10 ,  C07J17/00

Abstract: The present specification relates to a composition containing novel ginsenoside, (20S,24R)-6-O-β-D-glucopyranosyl(1→2)-β-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof as an active ingredient. The composition exhibits excellent effects in glycemic control, lipid metabolic control, cholesterol control, anti-obesity and blood circulation improvement.

公开(公告)号：US10022351B2

公开(公告)日：2018-07-17

申请号：US15160239

申请日：2016-05-20

Applicant: AMOREPACIFIC CORPORATION

Inventor： Byung Gyu Kim ,  Hyun Woo Jeong ,  Su Kyung Kim ,  Si Young Cho ,  Chan Woong Park ,  Dae Bang Seo ,  Wan Gi Kim ,  Sang Jun Lee

IPC: A61K31/34 ,  A23L2/52 ,  A61K36/258 ,  A23L33/11 ,  A23L33/105

Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

公开(公告)号：US09999611B2

公开(公告)日：2018-06-19

申请号：US15160197

申请日：2016-05-20

Applicant: AMOREPACIFIC CORPORATION

Inventor： Byung Gyu Kim ,  Hyun Woo Jeong ,  Su Kyung Kim ,  Si Young Cho ,  Chan Woong Park ,  Dae Bang Seo ,  Wan Gi Kim ,  Sang Jun Lee

IPC: A61K31/34 ,  A23L2/52 ,  A61K36/258 ,  A23L33/11 ,  A23L33/105

CPC classification number: A61K31/34 ,  A23L2/52 ,  A23L33/105 ,  A23L33/11 ,  A23V2002/00 ,  A61K36/258

Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

公开(公告)号：US09913823B2

公开(公告)日：2018-03-13

申请号：US14352444

申请日：2012-10-18

Applicant: AMOREPACIFIC CORPORATION

Inventor： Byung Gyu Kim ,  Hyun Woo Jeong ,  Su Kyung Kim ,  Si Young Cho ,  Chan Woong Park ,  Dae Bang Seo ,  Wan Gi Kim ,  Sang Jun Lee

IPC: A61K31/34 ,  A23L1/30 ,  A61K36/258 ,  A23L33/11 ,  A23L2/52 ,  A23L33/105

CPC classification number: A61K31/34 ,  A23L2/52 ,  A23L33/105 ,  A23L33/11 ,  A23V2002/00 ,  A61K36/258

Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

公开(公告)号：US20140371307A1

公开(公告)日：2014-12-18

申请号：US14352444

申请日：2012-10-18

Applicant: AMOREPACIFIC CORPORATION

Inventor： Byung Gyu Kim ,  Hyun Woo Jeong ,  Su Kyung Kim ,  Si Young Cho ,  Chan Woong Park ,  Dae Bang Seo ,  Wan Gi Kim ,  Sang Jun Lee

IPC: A61K31/34 ,  A23L1/30 ,  A61K36/258

CPC classification number: A61K31/34 ,  A23L2/52 ,  A23L33/105 ,  A23L33/11 ,  A23V2002/00 ,  A61K36/258

Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

Abstract translation: 本发明涉及式1化合物和SIRT 1活化剂，其包括其衍生物或其药学上可接受的盐作为活性成分。 本发明还涉及包含用于解毒的SIRT1激活剂，用于改善代谢紊乱，用于预防或改善眼部疾病或预防或改善免疫疾病的组合物。

公开(公告)号：US12252508B2

公开(公告)日：2025-03-18

申请号：US17267666

申请日：2019-06-27

Applicant: AMOREPACIFIC CORPORATION

Inventor： Yong Deog Hong ,  Hyun Woo Jeong

IPC: C07J17/00 ,  A23L33/105 ,  A61K8/63 ,  A61K9/00 ,  A61K31/704 ,  A61Q19/00 ,  C07H15/256

Abstract: The present specification relates to (20S,24R)-6-O-β-D-glucopyranosyl(1→2)-β-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, which is a novel ginsenoside, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof. The novel ginsenoside exhibits excellent anti-inflammatory effects.

公开(公告)号：US11633413B2

公开(公告)日：2023-04-25

申请号：US17031057

申请日：2020-09-24

Applicant: AMOREPACIFIC CORPORATION

Inventor： Yong Deog Hong ,  Hyun Woo Jeong

IPC: A61K31/7048 ,  A61K36/258 ,  A61K9/00

Abstract: The present disclosure relates to a composition comprising (20S,24R)-6-O-β-D-glucopyranosyl(1→2)-β-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, which is a novel ginsenoside, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof as an active ingredient. In addition, it relates to a method for preventing or improving menopausal symptoms, which comprises administering an effective amount of (20S,24R)-6-O-β-D-glucopyranosyl(1→2)-β-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof to a subject in need thereof. The novel ginsenoside has a superior effect of preventing or improving menopausal symptoms with a low risk of breast cancer.